GSK Plc (NYSE:GSK) has reportedly taken legal action against Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a Delaware federal court, alleging patent infringement concerning mRNA technology used in the COVID-19 vaccines.  The lawsuit contends that Pfizer and BioNTech’s Comirnaty vaccines violate GSK’s patents. Pfizer responded, expressing confidence in its intellectual property position regarding Comirnaty and asserting its intent to defend against GSK’s claims.  Reuters highlighted that GSK emphasized that its patents underpin the technology used in Pfizer and BioNTech’s COVID-19 mRNA vaccines. The company was willing to license these patents under reasonable terms to ensure ongoing vaccine access. This lawsuit contributes to a ...